TAIPEI, 24 novembre 2023 /PRNewswire/ — EirGenix Inc. (6589. TT) a annoncé aujourd’hui que son médicament biosimilaire du trastuzumab (EG12014) que son partenaire commercial Sandoz prévoit de commercialiser (150 mg en utilisation intraveineuse) avait reçu une autorisation de mise sur le…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.